• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: INTEGRA NEUROSCIENCES PR 2.5 CM BIOPATCH WITH 7.0 MM CENTER HOLE WITH MULTILINGUAL IFU

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

INTEGRA NEUROSCIENCES PR 2.5 CM BIOPATCH WITH 7.0 MM CENTER HOLE WITH MULTILINGUAL IFU Back to Search Results
Catalog Number 44152
Device Problems Delivered as Unsterile Product (1421); Device Operates Differently Than Expected (2913)
Patient Problems No Patient Involvement (2645); No Information (3190)
Event Date 12/03/2017
Event Type  malfunction  
Manufacturer Narrative
The device involved in the reported incident is not available for evaluation.An investigation has been initiated based on the reported information.
 
Event Description
It was reported that the product failed lab sterility test twice and was deemed sub-standard by distributor in (b)(4).
 
Manufacturer Narrative
Additional information received on april 19, 2018: how many samples were tested during each sterility test.How many samples failed? 2 what was the methodology used for the testing? unknown.Laboratory that performed testing qc moh authority.Laboratory investigation qc moh authority.Test controls results, area environmental controls, techniques used.Unknown.Reason for the testing as per egypt moh regulations 1st shipment of sterile registered products will be sampled and tested by qc moh authority.Rationale for retesting, based on usp the sterility testing can be repeated only under special circumstances where there is indication of a laboratory error.Why a retest was done? failure of the first testing.Microorganisms identification unknown.Lot distribution information (all lot sent to specific location? all lot distributed? qty sent to each end user or customer).Laboratory environmental, personnel training and all other elements of a lab investigation unknown.Why the test was repeated; failure of the first sterility test.Lot distribution dates, where the tested samples were stored after distribution and before testing.Distributor-quarantine.Samples evaluation before testing.Na.Any other testing conducted? potency? unknown.Have the test being conducted before? first time conducting the testing? as per egypt moh regulations 1st shipment of sterile registered products will be sampled and tested by qc moh authority.Investigation findings: documentation review of reported lot 1165816 (including sterilization cycle sps-177 / lot: le-16401) did not reveal any anomalies that could cause the reported sterility testing failure.No event, non-conformance and/or rework was recorded for the mentioned lot; therefore, it is concluded that the lot complied with all in-process inspections and testing requirements as specified in the manufacturing batch record and related procedures.Retain samples were evaluated.Visual inspection was performed to 100 retain samples.All samples had normal appearance and color (white ¿ no discoloration was observed).Sealing area was also inspected for each unit.All units were found to be sealed completely without any voids across the seal width.Forty (40) samples were delivered to the microbiology laboratory for sterility testing.The samples were sent to an approved external laboratory for testing.Test results were received indicating the samples showed no-growth after 14 days of incubation; thus, meeting the requirements of usp¿40 <70> for sterility.The complaint is considered not confirmed.Root cause: this investigation report has not found any indication that the reported sterility failure was caused by any of the processes performed at integra.There are validated controls that ensure all products are sold sterile as per current processes and procedures.
 
Manufacturer Narrative
Integra has completed their internal investigation: all boxes were opened and each unit was visually evaluated.Some sponges were found to be slightly discolored (off-white); nonetheless, as stated in the ifu, ¿over time the biopatch may turn yellow in color.This coloration does not reduce the antimicrobial efficacy of the dressing.¿ sealing area was also inspected for each unit (1,919 pouches).All units were found to be sealed completely without any voids across the seal width.No additional tests were requested since sterility testing had already been performed to the retain samples which are representative of the lot.There are no changes to the conclusions as originally reported based on the observations made from visual inspection of the retuned units.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
2.5 CM BIOPATCH WITH 7.0 MM CENTER HOLE WITH MULTILINGUAL IFU
Type of Device
BIOPATCH
Manufacturer (Section D)
INTEGRA NEUROSCIENCES PR
road 402 north, km 1.2
road 402 north, km 1.2
anasco PR 00610
MDR Report Key7314189
MDR Text Key101847628
Report Number3004608878-2018-00027
Device Sequence Number1
Product Code FRO
Combination Product (y/n)N
PMA/PMN Number
K003229
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign
Type of Report Initial,Followup,Followup
Report Date 02/22/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/05/2018
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Catalogue Number44152
Device Lot Number1165816
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer05/14/2018
Date Manufacturer Received05/31/2018
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
-
-